Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment

Research output: Contribution to journalJournal articlepeer-review

  1. Endokrinologi

    Research output: Chapter in Book/Report/Conference proceedingBook chapterCommunication

  2. Diabetes i familien – familien og diabetes

    Research output: Contribution to journalContribution to newspaper - Comment/debate

  • Ulrick Espelund
  • Henning Grønbaek
  • Gerda Elisabeth Villadsen
  • Kira Simonsen
  • Poul Frølund Vestergaard
  • Jens Otto Lunde Jørgensen
  • Allan Flyvbjerg
  • Hendrik Vilstrup
  • Jan Frystyk
View graph of relations

BACKGROUND: Previous studies have demonstrated an elevated IGF-II mRNA expression and protein levels in tumors and blood from patients with hepatocellular carcinoma (HCC), hereby suggesting a role of IGF-II as a pathogenic marker of HCC. We hypothesized that in HCC, an increased IGF-II secretion would translate into an elevated circulating IGF bioactivity, which would normalize following treatment.

METHODS: Patients with HCC (n=39) were studied before and after radio-frequency ablation and/or transarterial chemo-embolization. Baseline data were compared to healthy subjects (n=150) and patients with liver cirrhosis (n=41). Serum levels of IGF ligands and IGF binding proteins (IGFBPs) were determined using gold standard methods as well as novel assays and compared to liver function tests and HCC treatment status.

RESULTS: At baseline, HCC patients differed from cirrhosis patients and healthy controls regarding IGF-I (29 [23-37] vs. 12 [7-19] vs. 109 [103-116] μg/l), IGF-II (254 [224-288] vs. 118 [102-137] vs. 545 [525-566] μg/l) and IGF bioactivity (0.53 [0.41-0.68] vs. 0.29 [0.24-0.34] vs. 1.43 [1.33-1.53] μg/l) (mean [95% confidence interval], all age-adjusted P<0.001). All variables but IGFBP-2 were strongly associated with liver status (MELD score), and accordingly, differences were either attenuated or disappeared when adjusted for MELD score. There was no effect of treatment on any IGF variables.

CONCLUSIONS: The marked differences in IGF and IGFBP levels between patients with HCC, liver cirrhosis and healthy subjects are mainly explained by variations in liver status. Therefore, this study questions the clinical utility of circulating IGF variables as markers of HCC.

Original languageEnglish
JournalGrowth Hormone & IGF Research
Volume25
Issue number4
Pages (from-to)174-81
Number of pages8
ISSN1096-6374
DOIs
Publication statusPublished - Aug 2015
Externally publishedYes

    Research areas

  • Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Carcinoma, Hepatocellular, Case-Control Studies, Female, Humans, Insulin-Like Growth Factor Binding Protein 2, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I, Insulin-Like Growth Factor II, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Protein Precursors, Young Adult, Journal Article, Research Support, Non-U.S. Gov't

ID: 51690382